PFIC arises from autosomal recessive inheritance of pathogenic variants affecting genes that encode hepatocellular bile transport proteins. The specific causal gene differs across the recognized subtypes, resulting in distinct mechanistic disruptions of bile acid secretion, phospholipid secretion, or related transport functions. Per clinical review of one well-characterized subtype, pathogenic variants likely to severely impair the structure or function of the encoded transporter—such as nonsense and frameshift variants and large deletions—are more commonly associated with severe disease phenotypes. Missense variants more often produce milder phenotypes, though the genotype-phenotype relationship is imperfect and does not reliably predict individual disease course. Individuals within the same family carrying identical variants may exhibit substantially different clinical trajectories. The condition affects males and females equally given the autosomal recessive pattern present across PFIC subtypes.

PFIC diagnosis is established through a combination of clinical findings, laboratory evaluation, liver histology, and molecular genetic testing. Per clinical review of one characterized subtype, no consensus clinical diagnostic criteria have been formally published, and the diagnosis is suspected based on characteristic clinical findings including unremitting or episodic cholestasis, abnormal liver biopsy results, and laboratory markers of cholestatic liver disease. An important diagnostic consideration is distinguishing PFIC subtypes from the broader differential of inherited cholestatic disorders; several PFIC forms are distinguished by normal or low serum gamma-glutamyltranspeptidase levels, in contrast to more common cholestatic conditions characterized by elevated levels of this enzyme.

Given the clinical and genetic heterogeneity of PFIC, comprehensive genetic panel testing represents an important diagnostic component. Identification of pathogenic variants in the specific causal gene confirms subtype designation. The severity spectrum within a given subtype runs continuously rather than falling into discrete categories, and clinical classification requires integration of phenotypic and molecular findings.

Two pharmacological agents hold active FDA approval for the treatment of PFIC. Maralixibat chloride (LIVMARLI), approved April 2025 under a New Drug Application, and odevixibat (BYLVAY), approved July 2021, both hold active market status. Both agents function as ileal bile acid transporter inhibitors, reducing bile acid reabsorption from the intestinal tract and thereby lowering the systemic bile acid burden that drives cholestasis and pruritus. Per clinical review, ileal bile acid transporter inhibitor compounds have demonstrated reductions in bile acid levels and alleviation of pruritus in children with characterized PFIC subtypes. For individuals with advanced or treatment-refractory disease, liver transplantation represents a definitive intervention.

Several compounds have received orphan drug designation for PFIC, including investigational messenger RNA-based therapeutic approaches designed to restore specific bile transport protein expression. A bile acid analogue has also received orphan drug designation. Orphan drug designation reflects regulatory recognition of unmet medical need and is distinct from FDA approval; these agents remain investigational. Active clinical trials sponsored by pharmaceutical companies are ongoing, examining real-world effectiveness of approved treatments and exploring long-term outcomes.

The natural history of PFIC varies substantially across subtypes and individuals. Per clinical review of one well-characterized subtype, severe disease is characterized by infantile-onset cholestasis that progresses without effective treatment to cirrhosis, hepatic failure, and death. Even within a single subtype, however, the phenotypic spectrum ranges from severe, progressive disease to milder episodic forms. Some individuals with clinically diagnosed mild disease demonstrate hepatic fibrosis on liver biopsy, indicating that clinical presentation alone does not reliably predict the underlying pathological course. Individuals within the same family may follow divergent disease trajectories despite carrying identical genetic variants, suggesting the influence of additional modifying factors.

Progression to neoplasm has been documented in a proportion of reported cases. The availability of FDA-approved pharmacological therapies targeting bile acid transport may alter disease course and reduce cholestasis burden; long-term outcome data for these approved agents continue to accumulate through ongoing clinical studies and registries.

Active clinical investigation into PFIC involves multiple sponsored research programs, including outcomes studies evaluating real-world effectiveness and safety of approved treatments, long-term observational registries, and genetic characterization studies. Active trial sponsors include established pharmaceutical companies with rare disease programs. The published literature for PFIC encompasses a substantial body of classified publications, with case reports and case series representing the dominant publication type, alongside review articles and publications reporting clinical trial findings. Biomarker research and gene therapy publication activity have been documented in the PFIC research landscape.

Investigational therapeutic approaches under exploration include compounds that may improve intracellular protein trafficking in cells carrying specific causal variants, per clinical review. Messenger RNA-based strategies targeting restoration of bile transport protein expression are in active development and have received regulatory orphan drug designation. Research efforts span drug therapy, procedural interventions, and other investigational approaches, reflecting the breadth of the current PFIC research pipeline.